Cavity Shield®
Natural health product licensed in Canada
- Licence holder
- Solventum Canada Limited
- NPN or DIN-HM
- 80003433
- Status
- Inactive licence
- Licence date
- 16 May 2007
- Revision date
- Not provided
- Form
- Liquide
- Route of administration
- Dentaire
- Application type
- Non traditionnelle
Oral dose analysis does not apply without an established exclusively oral route.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source |
|---|---|
| Fluorure de sodium | 5 % |
Non-medicinal ingredients
xylitol, Bubblegum flavour (artificial), Alcool éthylique
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 0.25 mL | Not specified |
| Adultes | Not specified | 0.4 mL | Not specified |
Uses authorised in Canada
A fluoride-containing varnish to aid in the prevention of cavities (cavity varnish). For use a a cavity liner. Anti-caries / Anti-cavity
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
For Professional Use Only. Avoid use of this product in patients with know rosin/colophony allergies. Discontinue patient's use of other prescriptive fluoride preparations (i.e. gels, rinses) for 24 hours following CavityShield® application. Children taking fluoride supplements should discontinue use of supplements for several days following treatment. During the treatment perio, instruct the patient to avoid hard foods, brushing teeth and use of products containing alcohol (beverages, oral rinses). A thorough brushing and flossing will remove excess CavityShield® from tooth surfaces following treatment period. Keep out of reach of children.
- Contre-indications
Ulcerative gingivitis and stomatitis.
- Effets indésirables connus
Edematous swelling has been reported only in rare instances, especially following application to extensive surfaces. Dyspnea, although extremely rare, has occurred in asthmatic people. Nausea can occur in patients with know sensitive digestive systems, especially following extensive applications.
Source
Official Health Canada record, licence 80003433
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.